Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series (Q47877989)

6 February 2018

title

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series (English)

1 reference

6 February 2018

main subject

chronic myeloid leukemia

0 references

Alessandra Iurlo

1

0 references

Carmen Fava

Carmen Fava

11

0 references

Elisabetta Abruzzese

Elisabetta Abruzzese

3

0 references

Giuseppe Saglio

Giuseppe Saglio

28

0 references

Mario Tiribelli

Mario Tiribelli

16

0 references

Gianantonio Rosti

29

Gianantonio Rosti

1 reference

6 February 2018

19

Fausto Castagnetti

1 reference

6 February 2018

18

Gabriele Gugliotta

1 reference

6 February 2018

32

Michele Baccarani

1 reference

6 February 2018

24

Massimo Breccia

1 reference

6 February 2018

6

Roberto Latagliata

1 reference

6 February 2018

22

Bruno Martino

1 reference

6 February 2018

30

Giorgina Specchia

1 reference

6 February 2018

Massimiliano Bonifacio

5

Massimiliano Bonifacio

1 reference

6 February 2018

Gianni Binotto

14

Gianni Binotto

1 reference

6 February 2018

Daniele Cattaneo

12

Daniele Cattaneo

1 reference

6 February 2018

Fabrizio Pane

27

Fabrizio Pane

1 reference

6 February 2018

Mario Annunziata

4

Mario Annunziata

1 reference

6 February 2018

Antonella Gozzini

17

Antonella Gozzini

1 reference

6 February 2018

Federica Sorà

9

Federica Sorà

1 reference

6 February 2018

Monica Bocchia

26

Monica Bocchia

1 reference

6 February 2018

Patrizia Pregno

7

Patrizia Pregno

1 reference

6 February 2018

Luigiana Luciano

23

Luigiana Luciano

1 reference

6 February 2018

Cristina Bucelli

13

Cristina Bucelli

1 reference

6 February 2018

Dario Ferrero

8

Dario Ferrero

1 reference

6 February 2018

Giovanna Rege Cambrin

21

Giovanna Rege-Cambrin

1 reference

6 February 2018

Ester Maria Orlandi

10

Ester Maria Orlandi

1 reference

6 February 2018

Ester Pungolino

15

Ester Pungolino

1 reference

6 February 2018

Fabio Stagno

20

Fabio Stagno

1 reference

6 February 2018

Agostino Cortelezzi

31

Agostino Cortelezzi

1 reference

6 February 2018

author name string

Sara Galimberti

2

1 reference

6 February 2018

Simona Sica

25

1 reference

6 February 2018

publication date

2 October 2017

1 reference

6 February 2018

published in

Annals of Hematology

1 reference

6 February 2018

volume

97

1 reference

6 February 2018

issue

1

1 reference

6 February 2018

page(s)

95-100

1 reference

6 February 2018

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-017-3144-1

10.1007/S00277-017-3144-1

21 January 2018

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018